Laura Bukavina
@laurabukavinamd
Uro Onc- Translational Research Lead GU ONC @CleClinicUro π¬ bladder microbiomeπ§«π§ͺ ImmunoOnc @drexelmedicine @JohnsHopkinsSPH πΊπ¦@EUplatinum associate editor
ID: 2786427392
https://www.lerner.ccf.org/immunotherapy/bukavina/ 02-09-2014 18:09:32
5,5K Tweet
6,6K Followers
1,1K Following
π§΅1/12 π Understanding #NMIBC: Key Categories 𧬠π« Refractory: High-grade disease persists at 6 months despite BCG therapy. Includes any stage/grade progression by 3 months. π Relapsing: High-grade recurrence after disease-free state at 6 months post-BCG. π Intolerant:
